title: Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.
abstract: OBJECTIVE
  To investigate the effect of pyridostigmine on fatigue, physical performance, and muscle function in subjects with postpoliomyelitis syndrome.
  
  
  METHODS
  67 subjects with increased fatigue and new weakness in one quadriceps muscle showing neuromuscular transmission defects, were included in a randomised, double blind, placebo controlled trial of 60 mg pyridostigmine four times a day for 14 weeks. Primary outcome was fatigue (on the "energy" category of the Nottingham health profile). Secondary outcomes included two minute walking distance and quadriceps strength and jitter. Motor unit size of the quadriceps was studied as a potential effect modifier. The primary data analysis compared the changes from baseline in the outcomes in the last week of treatment between groups.
  
  
  RESULTS
  31 subjects treated with pyridostigmine and 31 subjects treated with placebo completed the trial. No significant effect of pyridostigmine was found on fatigue. The walking distance improved more in the pyridostigmine group than in the placebo group (by 7.2 m (6.0%); p<0.01). Subgroup analysis showed that a significant improvement in walking performance was only found in subjects with normal sized motor units. Quadriceps strength improved more in the pyridostigmine group than in the placebo group (by 6.7 Nm (7.2%); p = 0.15). No effect of pyridostigmine was found on jitter.
  
  
  CONCLUSIONS
  Pyridostigmine in the prescribed dose did not reduce fatigue in subjects with postpoliomyelitis syndrome. However, it may have a limited beneficial effect on physical performance, especially in subjects with neuromuscular transmission defects in normal sized motor units.
authors.affiliation: Department of Rehabilitation Medicine, VU University Medical Centre, Amsterdam, Netherlands. h.horemans@vumc.nl
authors.forename: H L D
authors.initials: HL
authors.lastname: Horemans
authors.forename: F
authors.initials: F
authors.lastname: Nollet
authors.forename: A
authors.initials: A
authors.lastname: Beelen
authors.forename: G
authors.initials: G
authors.lastname: Drost
authors.forename: D F
authors.initials: DF
authors.lastname: Stegeman
authors.forename: M J
authors.initials: MJ
authors.lastname: Zwarts
authors.forename: J B J
authors.initials: JB
authors.lastname: Bussmann
authors.forename: M
authors.initials: M
authors.lastname: de Visser
authors.forename: G J
authors.initials: GJ
authors.lastname: Lankhorst
mesh_terms: D000328:Adult; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D017079:Exercise Tolerance / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018763:Muscle Fatigue / Q000187:drug effects*; D016262:Postpoliomyelitis Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011597:Psychomotor Performance / Q000187:drug effects*; D011729:Pyridostigmine Bromide / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide